Combining BCL-2 inhibitors (venetoclax) with low-dose, mainly epigenetically active chemotherapy (e.g.azacytidine) modifies the clinical course of myelodysplastic syndromes/AML, especially with low proliferation activity, very positively with significantly improved survival [92]. This evidence concerns the gene BCL2 and acute myeloid leukemia.